Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) CEO Sells 2,800 Shares of Stock

Key Points

• Enliven Therapeutics CEO Samuel Kintz sold 2,800 shares of the company's stock at an average price of $20.03, resulting in a total transaction value of $56,084 and a 0.30% decrease in his ownership.
• The stock's current trading value is $18.57, reflecting a decline, with a market cap of $1.10 billion and a price-to-earnings ratio of -9.29.
• Multiple institutional investors have recently increased their stakes in Enliven Therapeutics, with 95.08% of the company's stock now owned by institutional investors and hedge funds.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 2,800 shares of the stock in a transaction dated Tuesday, September 23rd. The stock was sold at an average price of $20.03, for a total transaction of $56,084.00. Following the completion of the sale, the chief executive officer directly owned 919,092 shares in the company, valued at $18,409,412.76. This trade represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Friday, September 19th, Samuel Kintz sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.25, for a total value of $20,250.00.
• On Wednesday, September 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $19.09, for a total value of $95,450.00.
• On Tuesday, August 19th, Samuel Kintz sold 590 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $11,800.00.
• On Monday, August 18th, Samuel Kintz sold 10,393 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.02, for a total transaction of $208,067.86.
• On Thursday, July 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.52, for a total value of $281,500.00.

Enliven Therapeutics Stock Performance

NASDAQ ELVN traded down $0.63 on Thursday, reaching $18.57. 277,472 shares of the stock traded hands, compared to its average volume of 598,101. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -9.29 and a beta of 0.89. The company has a fifty day moving average price of $19.86 and a 200-day moving average price of $19.62.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. As a group, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Enliven Therapeutics by 3.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company's stock valued at $451,000 after purchasing an additional 718 shares during the period. Invesco Ltd. raised its position in Enliven Therapeutics by 4.3% during the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company's stock worth $440,000 after buying an additional 913 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after acquiring an additional 930 shares during the period. Quantbot Technologies LP boosted its holdings in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock valued at $90,000 after acquiring an additional 1,434 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Enliven Therapeutics by 10.2% in the fourth quarter. California State Teachers Retirement System now owns 20,914 shares of the company's stock worth $471,000 after acquiring an additional 1,940 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ELVN has been the subject of several recent research reports. The Goldman Sachs Group began coverage on Enliven Therapeutics in a research report on Monday, June 16th. They issued a "buy" rating and a $37.00 price target for the company. Robert W. Baird boosted their target price on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Finally, HC Wainwright raised their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Enliven Therapeutics presently has a consensus rating of "Buy" and an average price target of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.